Suggestions
Ester Caffarel-Salvador
Associate Director, Regenerative Medicine - Consultant - Scientific Advisor - Mentor - MIT's Innovator under 35 EU (2019)
Professional Background
Ester Caffarel-Salvador, PhD, is a distinguished professional recognized for her innovative contributions in the fields of biotechnology, biochemistry, and regenerative medicine. She was awarded the prestigious EU Innovator 35 under 35 accolade by the MIT Technology Review in 2019, which reflects her impact on the emerging technologies in health care. Currently serving as the Associate Director of Regenerative Medicine at LEO Pharma, Ester is at the forefront of exploring advanced therapeutic platforms that promise to transform patient care in critical and chronic health conditions.
With a career that spans academia, industry, and mentoring, Ester’s journey began with a strong academic foundation. She completed her undergraduate studies in Biotechnology and Biochemistry at the Universitat Autònoma de Barcelona, where her passion for science blossomed and she laid the groundwork for her future endeavors.
Education and Achievements
Ester continued her academic pursuit by obtaining a Doctorate in Pharmacy from Queen's University Belfast (QUB), where she not only excelled in her studies but also took on leadership roles in various industrial projects in collaboration with leading companies such as LTS and L’Oréal. This combination of education and practical experience allowed her to build a robust skill set that would serve her well in future roles.
In 2015, Ester made a significant leap in her career by joining the Laboratory of the prominent Professor Robert Langer at the Massachusetts Institute of Technology (MIT). At MIT, she collaborated with the renowned pharmaceutical company Novo Nordisk to design an innovative insulin pill, highlighting her commitment to devising solutions that could revolutionize diabetes management.
After her time at MIT, Ester played a pivotal role in executing the scientific strategy and spearheading business development for mytide therapeutics. This position underscored her ability to bridge the gap between scientific inquiry and commercialization, an essential skill in today’s fast-paced biotech landscape.
In December 2022, she transitioned to LEO Pharma, where she continues to push boundaries in regenerative medicine. In addition to her professional pursuits, Ester contributes to the community by mentoring rising talents in multiple programs at MIT, inspiring the next generation of innovators in the field. Her expertise makes her a sought-after advisor for international startups, further extending her influence in the biotechnology ecosystem.
Notable Achievements
- Recognition: Awarded EU Innovator 35 under 35 by the MIT Technology Review in 2019.
- Innovative Research: Collaborated on the design of an insulin pill with Novo Nordisk while at the Laboratory of Robert Langer at MIT.
- Leadership in Startups: Led scientific strategy and business development for mytide therapeutics, facilitating advancements and growth in the biotech sector.
- Mentorship: Actively mentors multiple programs at MIT, fostering innovation and the development of future leaders in biochemistry and biotechnology.
- Diverse Experience: Holds a breadth of experience ranging from teaching at various academic institutions to engaging in significant roles in prominent research organizations, showcasing her multifaceted expertise in the sciences and her commitment to education.
title
Ester Caffarel-Salvador's exceptional background in biotechnology and drug development has positioned her as a leading figure in regenerative medicine and innovation.
